DuPont Sustiva

Executive Summary

Randomized study of 1,200 patients shows anti-HIV combination treatment with non-nucleoside reverse transcriptase inhibitor Sustiva is more effective in suppressing viral load than a regimen including Merck's protease inhibitor Crixivan (indinavir), data presented at ICAAC indicate. According to a non completer=failure analysis, 60% of 154 patients taking Sustiva (efavirenz) + AZT/3TC had HIV levels below 400 copies/mL after 72 weeks of therapy vs. 40% of 148 patients treated with indinavir + AZT/3TC